首页> 外文期刊>Ocular immunology and inflammation >Juxtafoveal choroidal neovascularization secondary to persistent placoid maculopathy treated with intravitreal bevacizumab.
【24h】

Juxtafoveal choroidal neovascularization secondary to persistent placoid maculopathy treated with intravitreal bevacizumab.

机译:玻璃体腔注射贝伐珠单抗治疗继发于持续性乳突黄斑病的继发性凹状脉络膜新生血管。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: To describe a case of persistent placoid maculopathy (PPM) associated with juxtafoveal choroidal neovascularization (CNV) treated with intravitreal bevacizumab injection (IVBI). DESIGN: Interventional case report. METHODS: A 60-year-old patient referred for sudden vision loss was diagnosed with PPM complicated by a disciform scar in the right eye and juxtafoveal CNV in the left eye, undergoing 2 IVBIs. RESULTS: Best-corrected visual acuity passed from 20/32 to 20/20 after 2 IVBIs, with complete resolution of intraretinal and subretinal fluid and disappearance of fluorescein leakage. CONCLUSIONS: IVBI is a promising treatment option for juxtafoveal CNV secondary to PPM.
机译:目的:描述玻璃体腔注射贝伐珠单抗(IVBI)治疗伴有黄斑凹脉络膜新生血管(CNV)的持续性乳突黄斑病变(PPM)的病例。设计:介入病例报告。方法:一名因突然视力丧失而转诊的60岁患者被诊断为PPM,并伴有右眼盘状瘢痕和左眼近凹状CNV,接受了2次IVBI。结果:经过2次IVBI后,最佳矫正视力从20/32变为20/20,视网膜内和视网膜下液完全消失,荧光素渗漏消失。结论:IVBI是继发于PPM的近凹型CNV的有前途的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号